Dyslipidemia Archives - Endocrinology Advisor


Alirocumab May Have Greater CV Reduction Benefit in Patients With Diabetes

After an acute coronary syndrome event, alirocumab may offer greater risk reductions for future cardiovascular events in patients with diabetes vs those without diabetes, according to study results published in The Lancet Diabetes & Endocrinology. In the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; ClinicalTrials.gov Identifier:…

dietary supplement tablet

Adding PCSK9i to Niacin Therapy Reduces Lp(a) Concentrations

Adding proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) to background niacin therapy is shown to reduce lipoprotein(a) (Lp[a]) by approximately 15%, according to study results published in the Journal of Clinical Lipidology. In this study, 150 patients were divided into 2 groups: 136 received PCSK9i monotherapy and 14 received PCSK9i and niacin combination therapy. PCSK9i…

Next post in News